Aspect Biosystems Partners with InSCREENeX and Fraunhofer ITEM

(Aspect Biosystems) Aspect Biosystems Appoints Two New Members to its Board of Directors

Content provided by Aspect Biosystems.

VANCOUVER, BC, Canada – November 22, 2016 – Aspect Biosystems Ltd., a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering, has announced the appointment of James Hatton and Paul Drohan to its Board of Directors.

“We are extremely pleased to welcome James and Paul to our Board of Directors,” says Tamer Mohamed, President and CEO of Aspect Biosystems. “James and Paul bring significant corporate governance, strategic management, and operations experience to Aspect. Their valuable insight and experience in the life sciences sector is a tremendous asset to the company. I am confident they will make key contributions as we enter an exciting stage in our commercial growth and evolution as an industry leader in the field of 3D bioprinting.”

James Hatton, QC, is a partner at Farris, Vaughan, Wills & Murphy LLP. He has over 25 years’ experience in helping companies maximize the value of their intellectual property assets, focusing on licensing and related transactions. Mr. Hatton is a director of BC Hydro, the principal electricity utility for the province of British Columbia. He is also the chair of Life Sciences BC and a director of the Central City Foundation. Mr. Hatton was president of The Greater Vancouver Food Bank Society for six years, and remains an honorary life director of that organization. He has formerly served on boards including the board of governors of Royal Roads University and the governing council of the National Research Council of Canada, the government of Canada’s premier research, development and innovation organization.

“Aspect is a leader in 3D bioprinting and I am excited to be joining the Board of Directors,” said Mr. Hatton. “3D bioprinting will play an important role in improving and saving lives, and I look forward to working with the leadership team on the vast opportunities open to Aspect.”

Paul Drohan is a healthcare senior executive with over 25 years’ experience in the global biopharmaceutical industry. Most recently, he served as President and CEO of LifeSciences BC, an industry association that supports and represents the life sciences community of BC. He previously served as Global Senior Vice President for Genzyme (a Sanofi Company), where he led the organizations’ strategic, financial, and sales and marketing operations performance for the UK, Republic of Ireland, South Africa, Australia, New Zealand and Canada. Mr. Drohan has served on boards including Genzyme UK & Ireland, BioIndustry Association, and LifeSciences BC. He is also an advisor to national and regional governments on the development of the industrial life sciences sector and ecosystem.

“Aspect Biosystems’ 3D Printing innovation can revolutionize in vitro testing and regenerative medicine,” said Mr. Drohan. “The passion and desire to make a difference to health is the hallmark of the Aspect Team. The opportunity to serve on the Board and play a role in this company’s development and dynamic growth is exciting. It is with energy and determination for success that I have agreed to join the Board.”

About Aspect Biosystems

Aspect Biosystems Ltd. is a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. The company’s proprietary Lab-on-a-Printer™ platform technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal programs, Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to create physiologically and commercially relevant tissues. These tissues are used to advance and accelerate the discovery and development of new drugs and therapies.


Aspect Biosystems Ltd.
Tamer Mohamed
President & CEO

To read the original article, click here.